Sherif Samir Elzahwy

Sherif Samir Elzahwy

Auto-generated profile, based on publicly available information

Sherif Samir Elzahwy

Department of Cardiology, Faculty of Medicine – Ain Shams University

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2010 in Journal of Biological Chemistry
Verified
Journal Article
Open access
JAJoshua Abd Alla
Joshua Abd Alla
ALAndreas Langer
Andreas Langer
SESherif S. Elzahwy
Sherif S. Elzahwy
GAGökhan Arman-Kalcek
Gökhan Arman-Kalcek
TSThomas Streichert
Thomas Streichert
UQUrsula Quitterer
Ursula Quitterer
Many experimental and clinical studies suggest a relationship between enhanced angiotensin II release by the angiotensin-converting enzyme (ACE) and the pathophysiology of atherosclerosis. The atherosclerosis-enhancing effects of angiotensin II are complex and incompletely understood. To identify anti-atherogenic target genes, we performed microarray gene expression profiling of the aorta during atherosclerosis prevention with the ACE inhibitor, captopril. Atherosclerosis-prone apolipoprotein E (apoE)-deficient mice were used as a model to decipher susceptible genes regulated during atherosclerosis prevention with captopril. Microarray gene expression profiling and immunohistology revealed that captopril treatment for 7 months strongly decreased the recruitment of pro-atherogenic immune cells into the aorta. Captopril-mediated inhibition of plaque-infiltrating immune cells involved down-regulation of the C-C chemokine receptor 9 (CCR9). Reduced cell migration correlated with decreased numbers of aorta-resident cells expressing the CCR9-specific chemoattractant factor, chemokine ligand 25 (CCL25). The CCL25-CCR9 axis was pro-atherogenic, because inhibition of CCR9 by RNA interference in hematopoietic progenitors of apoE-deficient mice significantly retarded the development of atherosclerosis. Analysis of coronary artery biopsy specimens of patients with coronary artery atherosclerosis undergoing bypass surgery also showed strong infiltrates of CCR9-positive cells in atherosclerotic lesions. Thus, the C-C chemokine receptor, CCR9, exerts a significant role in atherosclerosis.

1 July 2011 in Cardiovascular & Hematological Agents in Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
SASaid AbdAlla
Said AbdAlla
XFXuebin Fu
Xuebin Fu
SESherif S. Elzahwy
Sherif S. Elzahwy
KKKristin Klaetschke
Kristin Klaetschke
TSThomas Streichert
Thomas Streichert
UQUrsula Quitterer
Ursula Quitterer
Chronic pressure overload and atherosclerosis are primary etiologic factors for cardiac hypertrophy and failure. However, mechanisms underlying the transition from hypertrophy to heart failure are incompletely understood. We analyzed the development of heart failure in mice with chronic pressure overload induced by aortic constriction and compared the results with aged apolipoprotein E-deficient mice suffering from advanced atherosclerosis. We combined cardiac function analysis by echocardiography and invasive hemodynamics with a comprehensive microarray gene expression study (GSE25765-8). The microarray data showed that the onset of heart failure induced by pressure overload or advanced atherosclerosis was accompanied by a strong up-regulation of key lipid metabolizing enzymes involved in fat synthesis, storage and oxidation. Cardiac lipid overload may be involved in the progression of heart failure by enhancing cardiomyocyte death. Up-regulation of the cardiac lipid metabolism was related to oxygen and ATP depletion of failing hearts because anti-ischemic treatment with ranolazine normalized the cardiac lipid metabolism and improved cardiac function. Vice versa, inhibition of cellular respiration and ATP generation by mild thiol-blocking with cystamine triggered the cardiac lipid metabolism and caused signs of heart failure. Cardiac tissue specimens of patients with heart failure also showed high protein levels of key fat metabolizing enzymes as well as lipid accumulation. Taken together, our data strongly indicate that up-regulation of the cardiac lipid metabolism and myocardial lipid overload are underlying the development of heart failure.

1 January 2011 in Forum on Immunopathological Diseases and Therapeutics
Verified
Journal Article
Closed access
YFYasser el Faramawy
Yasser el Faramawy
XFXuebin Fu
Xuebin Fu
SASara H. Agwa
Sara H. Agwa
ALAndreas Langer
Andreas Langer
SESherif S. Elzahwy
Sherif S. Elzahwy
UQUrsula Quitterer
Ursula Quitterer
Protein kinase C–mediated phosphorylation converts the raf kinase inhibitor protein (RKIP) into an inhibitor of the G protein–coupled receptor kinase 2 (GRK2). As a result of GRK2 inhibition, RKIP prevents receptor desensitization and enhances signaling stimulated by the classical substrate of GRK2, i.e., the Gs-coupled β-adrenergic receptor. The Gq/11-coupled angiotensin II AT1 receptor is another prototypic substrate of GRK2 in the cardiovascular system. However, the role of RKIP in Gq/11-coupled receptor signaling is not clear. Here, we show that overexpression of RKIP in kidney cells led to a significant increase of the AT1-stimulated calcium signal. In contrast, a phosphorylation-deficient mutant of RKIP that cannot act as GRK2 inhibitor had no effect. Analogously to the signal sensitization of kidney cells, RKIP increased the angiotensin II–stimulated hypertrophic response of cardiomyocytes. RNA interference studies revealed that endogenous RKIP levels of kidney cells and cardiomyocytes were sufficient to produce signal enhancement of AT1. Thus, RKIP acts as a physiological enhancer of angiotensin II–stimulated signaling in kidney cells and cardiomyocytes.

1 October 2021 in QJM: An International Journal of Medicine
Verified
Journal Article
Open access
PDF file
WIWalid Said Ibrahim
Walid Said Ibrahim
MFMohamed Moustafa Farouk
Mohamed Moustafa Farouk
MTMazen Tawfik
Mazen Tawfik
SESherif Samir Elzahwy
Sherif Samir Elzahwy
Background: Concern has always existed that statins might impair testosterone production either by reducing availability of its preferred substrate, that is, locally produced de novo cholesterol in the gonads and elsewhere, or by inhibiting steps in the steroidogenesis process, but this concern has been considered of little clinical significance. Objective: To demonstrate the impact of high doses of statins on testosterone level in ischemic heart disease patients and to compare it with the impact of low doses of statins. Patients and Methods: This study was approved by Ain Shams University. 90 candidates were randomly enrolled in the study divided into two groups, high dose group consisting of 45 patients and Low dose group including 45 patients. All patients were recruited from International Medical Center in Cairo, they were selected randomly from the outpatient clinic from the cardiology department. Results: In our study there were a significant reduction in total cholesterol, LDL and TGs in both low dose and high dose groups, but the effect on testosterone was quite different between them, the reduction in testosterone was about 33% from the baseline in the high dose group while in the low dose there was no significant reduction in the testosterone level. Conclusion: This study shows that statins reduce testosterone level. This finding does not demonstrate that androgens mediate any health effect of statins, but raises the question as to whether testosterone modulation plays a role in statins' effects on health, particularly among men where testosterone is an important hormone.